- TearClear Raises $22M in Series B Funding
- TearClear, a Boston, MA-based ophthalmic pharmaceutical company, raised $22M in a Series B funding round
- Bluestem Capital and Flying L Partners, who collaborated with Falcon Vision, a platform formed by KKR to advance innovation in ophthalmology
- Then the company intends to use the funds to advance multiple clinical programs in development, with two lead candidates in glaucoma paving the way for future indications
- Led by Chief Executive Officer Robert Dempsey, TearClear is an ophthalmic pharmaceutical company advancing two lead product candidates in glaucoma
- The company also announced the appointment of Stuart Raetzman, who most recently served as Chief Executive Officer of Galderma, to the TearClear Board of Directors
